Breast and ovarian cancer cells lacking function of either the BRCA1 or BRCA2 susceptibility gene products are deficient in homologous recombination and more sensitive to platinum-containing drugs [31-33]. This evidence concerns the gene BRCA1 and ovarian carcinoma.